8-K Announcements
6Material company update
Dec 9, 2025·SEC
Material company update
Oct 3, 2025·SEC
Material company update
Sep 2, 2025·SEC
XBiotech Inc.(XBIT)Earnings, Financials & Key Ratios
XBIT•NASDAQ
$2.33
Price updated Jun 25, 2026
AboutXBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.Show more
- Revenue$0
- EBITDA-$54M-32.6%
- Net Income-$46M-18.2%
- EPS (Diluted)-1.49-18.3%
- ROE-28.23%-46.9%
XBIT Price & Volume
XBiotech Inc. (XBIT) stock price & volume — 10-year historical chart
Loading chart...
XBIT Growth Metrics
XBiotech Inc. (XBIT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.14%
Return on Capital
10 Years-26.75%
5 Years-18.57%
3 Years-23.79%
Last Year-34.15%
Peers Comparison
Key metrics vs top competitors for XBiotech Inc. (XBIT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.33 | $71.04M | -1.56 | — | — | -28.23% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $26.69 | $3.34B | -205.31 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $116.46 | $9.51B | -31.56 | -16.72% | -612.17% | -25.02% | — |
Compare XBIT vs Peers
XBiotech Inc. (XBIT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XBIT SEC Filings & Documents
XBiotech Inc. (XBIT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when XBIT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XBIT Frequently Asked Questions
XBiotech Inc. (XBIT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is XBIT profitable?
XBiotech Inc. (XBIT) reported a net loss of $40.2M for fiscal year 2025.
Dividend & Returns
What is XBIT's return on equity?
XBiotech Inc. (XBIT) has a return on equity (ROE) of -28.2%. Negative ROE indicates the company is unprofitable.
What is XBiotech Inc.'s free cash flow?
XBiotech Inc. (XBIT) had negative free cash flow of $42.4M in fiscal year 2025, likely due to heavy capital investments.